Genmab’s DARZALEX (daratumumab) collaboration partner, Janssen Biotech, has triggered a $20 million milestone payment. The milestone relates to progress in the ongoing Phase III ANDROMEDA study of daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone in amyloidosis.
 

Daratumumab is a human monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death.

“This milestone marks an important step in the development of daratumumab outside of multiple myeloma,” said Jan van de Winkel, Ph.D., chief executive officer of Genmab. “There is currently no cure for amyloidosis and we look forward to seeing the results of daratumumab treatment in this indication.”